Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4188703 | Psiquiatría Biológica | 2013 | 6 Pages |
Abstract
Desvenlafaxine (DESV) is a new antidepressant within the group of serotonin-norepinephrine reuptake inhibitors (SNRI). Various controlled clinical trials have demonstrated its efficacy in the treatment of adult patients with a major depressive disorder. These studies have evaluated the efficacy of DESV in doses that varied between 50Â mg and 400Â mg/day. However, the therapeutic dose of DESV has been established at 50Â mg/ day, with no additional therapeutic benefits being observed at higher doses. The tolerability and safety profile of DESV at this dose is very favourable, a fact that is associated with a minimal impact on the cytochrome P450 system which gives it the additional advantage of a lower risk of pharmacokinetic interactions. This review provides a summary of the pharmacological data of DESV, as well as the pre-clinical and clinical results on its efficacy and safety.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
NarcÃs Cardoner Álvarez,